As a result of “uncertain and unpredictable markets, Novo Nordisk is considering abandoning its longterm financial target and slashing 3,000 jobs from its global workforce, Endpoints News reports, citing Danish business newspaper Borsen. The giant diabetes drugmaker intends to unveil its cost reduction package along with its Q2 results in August, the report says. Such plans include an adjustment of its growth forecast, which the company put at 5% as recently as May, the report notes. Shares of Novo Nordisk are down 2.1% in New York after the news
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.